Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Lymphoma

  Free Subscription


Articles published in Leukemia

Retrieve available abstracts of 39 articles:
HTML format
Text format



Single Articles


    January 2019
  1. DODERO A, Guidetti A, Tucci A, Barretta F, et al
    Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma.
    Leukemia. 2019 Jan 10. pii: 10.1038/s41375-018-0320.
    PubMed     Text format    


    December 2018
  2. EDGINTON-WHITE B, Cauchy P, Assi SA, Hartmann S, et al
    Global long terminal repeat activation participates in establishing the unique gene expression programme of classical Hodgkin lymphoma.
    Leukemia. 2018 Dec 13. pii: 10.1038/s41375-018-0311.
    PubMed     Text format     Abstract available


  3. PENG RJ, Han BW, Cai QQ, Zuo XY, et al
    Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma.
    Leukemia. 2018 Dec 13. pii: 10.1038/s41375-018-0324.
    PubMed     Text format     Abstract available


    October 2018
  4. FRASER G, Cramer P, Demirkan F, Silva RS, et al
    Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leukemia. 2018 Oct 12. pii: 10.1038/s41375-018-0276.
    PubMed     Text format     Abstract available


  5. HOUOT R, Cartron G, Bijou F, de Guibert S, et al
    Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.
    Leukemia. 2018 Oct 5. pii: 10.1038/s41375-018-0282.
    PubMed     Text format    


    August 2018
  6. PRUTSCH N, Gurnhofer E, Suske T, Liang HC, et al
    Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.
    Leukemia. 2018 Aug 21. pii: 10.1038/s41375-018-0239.
    PubMed     Text format     Abstract available


  7. BORCHMANN S, Muller H, Haverkamp H, Baues C, et al
    Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG).
    Leukemia. 2018 Aug 21. pii: 10.1038/s41375-018-0240.
    PubMed     Text format     Abstract available


    April 2018
  8. HU T, Wu Q, Chong Y, Qin H, et al
    FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome.
    Leukemia. 2018 Apr 2. pii: 10.1038/s41375-018-0124.
    PubMed     Text format     Abstract available


    March 2018
  9. SCHLEUSSNER N, Merkel O, Costanza M, Liang HC, et al
    The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma.
    Leukemia. 2018 Mar 28. pii: 10.1038/s41375-018-0045.
    PubMed     Text format     Abstract available


  10. SUN W, Malvar J, Sposto R, Verma A, et al
    Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.
    Leukemia. 2018 Mar 15. pii: 10.1038/s41375-018-0094.
    PubMed     Text format     Abstract available


    February 2018
  11. GALLARDO F, Bertran J, Lopez-Arribillaga E, Gonzalez J, et al
    Novel phosphorylated TAK1 species with functional impact on NF-kappaB and beta-catenin signaling in human Cutaneous T-cell lymphoma.
    Leukemia. 2018 Feb 22. pii: 10.1038/s41375-018-0066.
    PubMed     Text format     Abstract available


  12. ARAF S, Wang J, Korfi K, Pangault C, et al
    Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma.
    Leukemia. 2018 Feb 8. pii: 10.1038/s41375-018-0043.
    PubMed     Text format    


  13. NAIRISMAGI M-, Gerritsen ME, Li ZM, Wijaya GC, et al
    Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-017-0004.
    PubMed     Text format     Abstract available


  14. RULE S, Jurczak W, Jerkeman M, Rusconi C, et al
    Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-018-0023.
    PubMed     Text format    


  15. KLYMENKO T, Bloehdorn J, Bahlo J, Robrecht S, et al
    Lamin B1 regulates somatic mutations and progression of B-cell malignancies.
    Leukemia. 2018;32:364-375.
    PubMed     Text format     Abstract available


  16. LIU E, Tong Y, Dotti G, Shaim H, et al
    Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
    Leukemia. 2018;32:520-531.
    PubMed     Text format     Abstract available


    November 2017
  17. HARTMANN K, Illing A, Leithauser F, Baisantry A, et al
    Gene dosage reductions of Trf1 and/or Tin2 induce telomere DNA damage and lymphoma formation in aging mice.
    Leukemia. 2017 Nov 10. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  18. GERMINI D, Tsfasman T, Klibi M, El-Amine R, et al
    HIV Tat induces a prolonged MYC relocalization next to IGH in circulating B-cells.
    Leukemia. 2017;31:2515-2522.
    PubMed     Text format     Abstract available


    October 2017
  19. HU G, Dasari S, Asmann YW, Greipp PT, et al
    Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma.
    Leukemia. 2017 Oct 13. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  20. SOMMERMEYER D, Hill T, Shamah SM, Salter AI, et al
    Fully human CD19-specific chimeric antigen receptors for T-cell therapy.
    Leukemia. 2017;31:2191-2199.
    PubMed     Text format     Abstract available


  21. CHEN KH, Wada M, Pinz KG, Liu H, et al
    Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.
    Leukemia. 2017;31:2151-2160.
    PubMed     Text format     Abstract available


    September 2017
  22. JIA YJ, Liu ZB, Wang WG, Sun CB, et al
    HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma.
    Leukemia. 2017 Sep 28. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  23. VRZALIKOVA K, Ibrahim M, Vockerodt M, Perry T, et al
    S1PR1 drives a feed forward signalling loop to regulate BATF3 and the transcriptional programme of hodgkin lymphoma cells.
    Leukemia. 2017 Sep 7. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    August 2017
  24. FUJISAWA M, Sakata-Yanagimoto M, Nishizawa S, Komori D, et al
    Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma.
    Leukemia. 2017 Aug 23. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  25. ZAMO A, Pischimarov J, Schlesner M, Rosenstiel P, et al
    Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole exome sequencing.
    Leukemia. 2017 Aug 21. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  26. KARUBE K, Enjuanes A, Dlouhy I, Jares P, et al
    Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.
    Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    July 2017
  27. CHEADLE EJ, Lipowska-Bhalla G, Dovedi SJ, Fagnano E, et al
    A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.
    Leukemia. 2017 Jul 28. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  28. YAO Z, Deng L, Xu-Monette ZY, Manyam GC, et al
    Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.
    Leukemia. 2017 Jul 12. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  29. JAIN N, Zhu H, Khashab T, Ye Q, et al
    Targeting nucleolin for better survival in diffuse large B-cell lymphoma.
    Leukemia. 2017 Jul 10. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    June 2017
  30. SUN B, Fiskus W, Qian Y, Rajapakshe K, et al
    BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells.
    Leukemia. 2017 Jun 30. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  31. LOLLIES A, Hartmann S, Schneider M, Bracht T, et al
    An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma.
    Leukemia. 2017 Jun 29. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    May 2017
  32. KASENDA B, Ihorst G, Schroers R, Korfel A, et al
    High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma-a prospective multicentre trial by the German cooperative PCNSL study group.
    Leukemia. 2017 May 31. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    April 2017
  33. VAN DER MEULEN M, Dinmohamed AG, Visser O, Doorduijn JK, et al
    Improved survival in primary central nervous system lymphoma up to age 70 only: A population-based study on incidence, primary treatment and survival in the Netherlands, 1989-2015.
    Leukemia. 2017 Apr 28. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    March 2017
  34. ATSAVES V, Tsesmetzis N, Chioureas D, Kis L, et al
    PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large cell lymphoma.
    Leukemia. 2017 Mar 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  35. DZIKIEWICZ-KRAWCZYK A, Kok K, Slezak-Prochazka I, Robertus JL, et al
    ZDHHC11 and ZDHHC11B are critical novel components of the oncogenic MYC-miR-150-MYB network in Burkitt lymphoma.
    Leukemia. 2017 Mar 23. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    January 2017
  36. MONJEZI R, Miskey C, Gogishvili T, Schleef M, et al
    Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors.
    Leukemia. 2017;31:186-194.
    PubMed     Text format     Abstract available


  37. RUELLA M, Kenderian SS, Shestova O, Klichinsky M, et al
    Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.
    Leukemia. 2017;31:246-248.
    PubMed     Text format    


    March 2016
  38. GONDEK LP, Zheng G, Ghiaur G, DeZern AE, et al
    Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation.
    Leukemia. 2016 Mar 15. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


    February 2016
  39. MIRANDA MB, Lauseker M, Kraus MP, Proetel U, et al
    Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment- long-term observation in CML Study IV.
    Leukemia. 2016 Feb 9. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: